Generation Bio Co. (NASDAQ:GBIO) Short Interest Update

Generation Bio Co. (NASDAQ:GBIO) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 2,068 shares, a decline of 94.5% from the December 31st total of 37,732 shares. Based on an average daily trading volume, of 59,001 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are short sold. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 59,001 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on GBIO shares. Wedbush set a $5.50 price objective on shares of Generation Bio and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Generation Bio in a research note on Thursday, January 22nd. Zacks Research raised Generation Bio to a “hold” rating in a research note on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Generation Bio in a report on Friday, November 7th. Finally, Citigroup restated a “market perform” rating on shares of Generation Bio in a report on Wednesday, December 17th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.88.

Institutional Investors Weigh In On Generation Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in GBIO. AQR Capital Management LLC acquired a new position in Generation Bio in the 1st quarter worth $36,000. Acadian Asset Management LLC lifted its holdings in shares of Generation Bio by 54.3% in the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after purchasing an additional 407,843 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Generation Bio during the second quarter worth about $47,000. Marshall Wace LLP bought a new position in shares of Generation Bio during the second quarter worth about $37,000. Finally, Militia Capital Partners LP bought a new position in shares of Generation Bio during the second quarter worth about $174,000. 95.22% of the stock is currently owned by institutional investors and hedge funds.

Generation Bio Stock Performance

NASDAQ:GBIO traded up $0.04 on Thursday, reaching $5.62. The company’s stock had a trading volume of 49,461 shares, compared to its average volume of 95,737. Generation Bio has a 1-year low of $3.00 and a 1-year high of $8.66. The business’s 50-day moving average price is $5.45 and its two-hundred day moving average price is $5.55. The firm has a market cap of $37.88 million, a PE ratio of -0.60 and a beta of 2.05.

Generation Bio (NASDAQ:GBIO) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($3.18) by $2.36. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%.The business had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $0.66 million. As a group, sell-side analysts expect that Generation Bio will post -1.75 EPS for the current year.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.